Drug intelligence / Profile preview

AXN-032

Development stage: Preclinical
Lead developer: Axonova Pharma

Overview

AXN-032 is an indigenous plant extract characterized by UHPLC-UV/MS, developed by Axonova. It has demonstrated high neurotrophic activity in in vitro neuron cell models, potentially acting via the BDNF/TrkB pathway by showing potent TrkB activating activity. It has shown promising neuroprotective properties in cellular models of Alzheimer's and Parkinson's diseases.

Targets

NTRK2 (Tropomyosin-related kinase receptor type B)

Beyond the preview

Go deeper on AXN-032.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AXN-032.

Explore the full profile